Compare Alibaba Group (BABA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs GeneDx Holdings Corp — how do they compare? Alibaba Group trades at $124.73 (market cap $309.65B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: Alibaba Group is far larger — about 133.5× GeneDx Holdings Corp's market cap, and Alibaba Group pays a 0.79% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BABA | WGS | |
|---|---|---|
Market Cap | $309.65B | $2.32B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $189.34 | $167.51 |
52-Week Low | $94.83 | $34.51 |
Enterprise Value | $304.43B | $2.35B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.
Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
